COMMUNIQUÉS West-GlobeNewswire

Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years

06/11/2017 - 07:15

For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx ® have no radiographic progression of the spine at 4 years[1] These new data also confirm sustained [...]

Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL

06/11/2017 - 07:10

Application follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis is working closely with [...]

Medtronic Receives CE Mark for the World's Smallest Fully Implantable Spinal Cord Stimulator and Announces European Launch of the Intellis Platform

06/11/2017 - 07:00

New Neurostimulation System Is a Non-Opioid Alternative for Chronic Pain and Offers Personalized Pain Relief and Advanced Activity Tracking DUBLIN - November 6, 2017 - Medtronic plc (NYSE:MDT) today announced that it [...]

VALNEVA Annonce sa Participation aux Conférences "Healthcare" 2017 de Jefferies et Stifel

06/11/2017 - 07:00

Valneva Annonce sa Participation aux Conférences "Healthcare" 2017 de Jefferies et Stifel Lyon (France), 6 novembre 2017 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à la [...]

TiGenix announces partial conversion of bonds

06/11/2017 - 07:00

PRESS RELEASE TiGenix announces partial conversion of bonds Leuven (BELGIUM) - November 6, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting [...]

TiGenix annonce une conversion partielle d'obligations

06/11/2017 - 07:00

COMMUNIQUÉ DE PRESSE TiGenix annonce une conversion partielle d'obligations Louvain (BELGIQUE) - le 6 novembre 2017, 7:00h CET - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société biopharmaceutique de pointe axée [...]

VALNEVA to Present at Jefferies and Stifel 2017 Healthcare Conferences

06/11/2017 - 07:00

Valneva to Present at Jefferies and Stifel 2017 Healthcare Conferences Lyon (France), November 06, 2017 - Valneva SE ("Valneva" or "the Company"), a leading commercial stage biotech company focused on developing [...]

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

05/11/2017 - 15:00

Galapagos presents data from DARWIN 3, other filgotinib studies and Galapagos' GLPG1972 at American College of Rheumatology Meeting 2017 Mechelen, Belgium; 5 November 2017; 3 PM CET - Galapagos NV (Euronext & NASDAQ [...]

XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions

03/11/2017 - 17:16

Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary Thrombosis AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the [...]

Shire plc : Director/PDMR Shareholding

03/11/2017 - 11:00

Director/PDMR Shareholding November 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]

Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA

03/11/2017 - 10:36

Reference is made to Targovax ASA's (the "Company") stock exchange notice of 27 October 2017 relating to the board of director's resolutions to increase the share capital in connection with exercise of employee options [...]

NICOX : Suite à l'approbation de VYZULTA, état des activités, des programmes de développement de son portefeuille de produits et point financier

03/11/2017 - 07:30

Communiqué de presse Nicox : suite à l'approbation de VYZULTA TM , état des activités, des programmes de développement de son portefeuille de produits et point financier VYZULTA TM (solution ophtalmique de [...]

Nicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives

03/11/2017 - 07:30

Press Release Nicox Highlights VYZULTA TM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives ................................... VYZULTA TM (latanoprostene bunod ophthalmic solution [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

03/11/2017 - 07:10

REGULATED INFORMATION GHENT, Belgium, 3 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

03/11/2017 - 07:05

pdf version of the press release This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

03/11/2017 - 07:00

REGULATED INFORMATION GHENT, Belgium, 3 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

BAUSCH + LOMB ET NICOX ANNONCENT L'APPROBATION DE LA FDA POUR VYZULTA(TM) (SOLUTION OPHTALMIQUE DE LATANOPROSTÈNE BUNOD), 0,024%

02/11/2017 - 21:45

Contacts: Valeant Relations Investisseurs : Arthur Shannon arthur.shannon@valeant.com +1-514-856-3855 +1-877-281-6642 (toll free) Media: Lainie Keller lainie.keller@valeant.com +1-908-927-0617 Kristy Marks kristy.marks@ [...]

Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program

02/11/2017 - 21:30

Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the Generation Program, which [...]

Medtronic Releases Fiscal Year 2017 Integrated Performance Report

02/11/2017 - 19:00

Report Highlights Company's Global Financial, Social, and Environmental Impact DUBLIN - November 2, 2017 - Medtronic plc (NYSE:MDT) announces the release of its fiscal year 2017 Integrated Performance Report. The report [...]